PTO/SB/08a (07-09) Approved for use through 07/31/2012, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10785230	
Filing Date		2004-02-26	
First Named Inventor	Tadamitsu Kishimoto		
Art Unit		1642	
Examiner Name	Laura B. Goddard		
Attorney Docket Number		046124-5042-01	

					U.S.I	PATENTS				
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>			Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevar Figures Appear		
	1									
If you wis	h to a	ı dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.			
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS			
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date		Name of Pate of cited Docu	entee or Applicant iment	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	olease click the Ade	d buttor	n.	
				FOREIG	GN PAT	ENT DOCUM	ENTS			
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i		Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1	0666868	EP		B2	1995-08-16	Genentech, Inc.			
If you wis	h to a	dd additional Foreign Pa	atent Do	cument	citation	information p	lease click the Add	button		
			NON	I-PATEN	NT LITE	RATURE DO	CUMENTS			
Examiner Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.									<b>T</b> 5	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

 Application Number
 10785230

 Filling Date
 2004-02-26

 First Named Inventor
 Tadamitsu Kishimoto

 Art Unit
 1642

 Examiner Name
 Laura B. Goddard

 Attorney Docket Number
 046124-5042-01

1	Aluti et al. (1997), The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood, J. Exp Med. 185:111-20.	
2	Amara et al. (1997), HIV coreceptor downregulation as antiviral principle: SDF-1 alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication, J. Exp Med. 188:139-46.	
3	Asahara et al. (1997), Isolation of putative progenitor endothelial cells for angiogenesis, Science 275:964-7.	
4	Bouck et al. (1996), How tumors become angiogenic, Adv Cancer Res. 69:135-74.	
5	Carmeliet (1996), Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele, Nature 380.435-9.	
6	Carmeliet P, Jain RK. (2000), Angiogenesis in cancer and other diseases, Nature 407:249-57.	
7	Chen et al. (2003), Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in Vitro, Cancer Res. 63:4801-4	
8	Ferrara et al. (1996), Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene, Nature 380: 439-42.	
9	Folkman, J. (1971), Tumor angiogenesis: Therapeutic Implications. New Engl. J. Med. 285:1182-6.	
10	Folkman, J. (1990), What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst. 82.4-6.	
11	Haeberlin et al. (1993), In vitro evaluation of dexamethasone-beta-D-glucuronide for colon-specific drug delivery, Pharm Res. 10:1553-62.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B.G

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10785230		
Filing Date		2004-02-26		
First Named Inventor	Tadar	nitsu Kishimoto		
Art Unit		1642		
Examiner Name	Laura	B. Goddard		
Attorney Docket Number		046124-5042-01		

	12	Leon, L. (2005), Invited review: The use of gene knockout mice in thermoregulation studies, J. Thermal Biol. 30:273-88.					
	13	Ma et al. (1998), Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice, Proc Natl Acad Sci USA 95:9448-53.					
	14	Müller, U. (1999), Ten years of gene targeting: targeted mouse mutants, from vector design to phenotype analysis. Mechanism of Development 82:3-21.					
	15	Shalaby et al. (1995), Failure of blood-island formation and vasculogenesis in Fik-1-deficient mice, Nature 376: 62-6.					
	16	Smith et al. (2004), CXCR4 regulates growth of both primary and metastatic breast cancer, Cancer Res. 64: 8604-12.					
	17	Spano et al. (2004), Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome, Ann Oncol. 15:613-7.					
	18	Weis et al. (2008), Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK, J. Cell Biol. 181:43-50.					
	19	Zou et al. (1998), Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development, Nature 393:524-5.					
If you wis	h to a	dd additional non-patent literature document citation information please click the Add button					
		EXAMINER SIGNATURE					
Evamine	Sign	ature // aura R Goddard/ Date Considered 04/00/040					

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patent Documents at <a href="https://www.USPTO.GOV">www.USPTO.GOV</a> or MPEP 901.04. It Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precode the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST.16 if possible. Applicant is to place a check mark here if English language translation is attached.